Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly.

OBJECTIVE--To investigate the relation between mortality and treated systolic and diastolic blood pressures. DESIGN--Randomised double blind placebo controlled trial. Mortality in the two treatment groups was examined in thirds of treated systolic and diastolic blood pressures. PATIENTS--339 And 352 patients allocated to placebo and active treatment, respectively. The groups were similar at randomisation in sex ratio (70% women), mean age (71.5 years), blood pressure (182/101 mm Hg), and proportion of patients with cardiovascular complications (35%). MEASUREMENTS AND MAIN RESULTS--In the placebo group total mortality rose with increasing systolic pressure whereas it had a U shaped relation with diastolic pressure, the total lowest mortality being in patients in the middle third of the distribution of diastolic pressure. In the group given active treatment total mortality showed a U shaped relation with systolic pressure and an inverse association with treated diastolic pressure. In both groups cardiovascular and non-cardiovascular mortality followed the same trends as total mortality. The increased mortality in the lowest thirds of pressure was not associated with an increased proportion of patients with cardiovascular complications at randomisation or with a fall in diastolic pressure exceeding the median fall in pressure in each group. In contrast, patients in the lowest thirds of pressure showed greater decreases in body weight and haemoglobin concentration than those in the middle and upper thirds of pressure. CONCLUSIONS--In patients taking active treatment total mortality was increased in the lowest thirds of treated systolic and diastolic blood pressures. This increased mortality is not necessarily explained by an exaggerated reduction in pressure induced by drugs as for diastolic pressure a U shaped relation also existed during treatment with placebo. In addition, patients in the lowest thirds of systolic and diastolic pressures were characterised by decreases in body weight and haemoglobin concentration, and the patients in the lowest thirds of diastolic pressure taking active treatment also by an increased non-cardiovascular mortality, suggesting some deterioration of general health.

[1]  J. Lanke,et al.  Both high and low blood pressures risk indicators of death in middle-aged males. Isotonic regression of blood pressure on age applied to data from a 13-year prospective study. , 2009, Acta medica Scandinavica.

[2]  D. Beevers.  Overtreating hypertension. , 1988, BMJ.

[3]  J. Cruickshank.  Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. , 1988, BMJ.

[4]  R. Newson,et al.  Treated blood pressure, rather than pretreatment, predicts survival in hypertensive patients. A report from the DHSS Hypertension Care Computing Project (DHCCP). , 1988, Journal of hypertension.

[5]  J. Coope,et al.  The prognostic significance of blood pressure in the elderly. , 1988, Journal of human hypertension.

[6]  P. Waller,et al.  Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? , 1988, Journal of human hypertension.

[7]  C. Bulpitt,et al.  The relationship between a low treated blood pressure and IHD mortality: a report from the DHSS Hypertension Care Computing Project (DHCCP). , 1988, Journal of human hypertension.

[8]  L Wilhelmsen,et al.  Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Göteborg, Sweden. , 1987, JAMA.

[9]  S. Strandgaard,et al.  WHY DOES ANTIHYPERTENSIVE TREATMENT PREVENT STROKE BUT NOT MYOCARDIAL INFARCTION? , 1987, The Lancet.

[10]  K. Pennert,et al.  Low Mortality from All Causes, Including Myocardial Infarction, in Well‐Controlled Hypertensives Treated with a Beta‐Blocker Plus Other Antihypertensives , 1987, Journal of hypertension.

[11]  J. Thorp,et al.  LOWERING BLOOD PRESSURE , 1987, The Lancet.

[12]  J. Cruickshank,et al.  BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE , 1987, The Lancet.

[13]  C. Bulpitt,et al.  Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub-group analysis on entry stratification. , 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[14]  T S Warrender,et al.  Randomised trial of treatment of hypertension in elderly patients in primary care. , 1986, British medical journal.

[15]  J. Hoey.  An Introduction to Epidemiologic Methods , 1986 .

[16]  C. Bulpitt,et al.  EFFICACY OF ANTIHYPERTENSIVE DRUG TREATMENT ACCORDING TO AGE, SEX, BLOOD PRESSURE, AND PREVIOUS CARDIOVASCULAR DISEASE IN PATIENTS OVER THE AGE OF 60 , 1986, The Lancet.

[17]  J. Lanke,et al.  U-shaped association between mortality and blood pressure in a thirteen-year prospective study. , 1986, Family practice.

[18]  C. Bulpitt,et al.  Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial , 1985, The Lancet.

[19]  K. Green.  The role of hypertension and downward changes of blood pressure in the genesis of coronary atherosclerosis and acute myocardial ischemic attacks. , 1982, American heart journal.

[20]  I. Stewart.  RELATION OF REDUCTION IN PRESSURE TO FIRST MYOCARDIAL INFARCTION IN PATIENTS RECEIVING TREATMENT FOR SEVERE HYPERTENSION , 1979, The Lancet.

[21]  T. Anderson.  RE-EXAMINATION OF SOME OF THE FRAMINGHAM BLOOD-PRESSURE DATA , 1978, The Lancet.

[22]  W. Kannel,et al.  Role of Blood Pressure in Cardiovascular Disease: the Framingham Study , 1975, Angiology.

[23]  D. Gau.  MILD HYPERTENSION: IS THERE PRESSURE TO TREAT? , 1988 .

[24]  I. Stewart.  beta-Adrenoceptor blockade and the incidence of myocardial infarction during treatment of severe hypertension. , 1982, British journal of clinical pharmacology.